Jo-Anne H van Burik
Overview
Explore the profile of Jo-Anne H van Burik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
1070
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patnaik M, Hammerschmidt D, van Burik J, Jessurun J, Smyth P
Minn Med
. 2008 Dec;
91(11):30-3.
PMID: 19108542
Leprosy is uncommon in North America. Because it has a prolonged incubation period and can masquerade with a variety of manifestations, many patients with leprosy experience a significant delay in...
2.
van Burik J, Carter S, Freifeld A, High K, Godder K, Papanicolaou G, et al.
Biol Blood Marrow Transplant
. 2007 Nov;
13(12):1487-98.
PMID: 18022579
Serious infections are a major obstacle limiting the usefulness of unrelated donor marrow transplantation. Graft-versus-host disease (GVHD) and its therapy are associated with a high risk of opportunistic infection. In...
3.
Copelan E, Casper J, Carter S, van Burik J, Hurd D, Mendizabal A, et al.
Biol Blood Marrow Transplant
. 2007 Nov;
13(12):1469-76.
PMID: 18022577
The primary cause of death (COD) provides important information in many studies of hematopoietic stem cell transplantation (HSCT). A panel of experts critically assessed the CODs submitted by 15 transplantation...
4.
Walker C, van Burik J, De For T, Weisdorf D
Biol Blood Marrow Transplant
. 2007 Aug;
13(9):1106-15.
PMID: 17697973
Cytomegalovirus (CMV) infection is an important complication following allogeneic hematopoietic stem cell transplant (HSCT), but the natural history in the cord blood setting has not been well studied. We assessed...
5.
Foy P, van Burik J, Weisdorf D
Biol Blood Marrow Transplant
. 2007 Feb;
13(4):440-3.
PMID: 17287156
Invasive aspergillosis is difficult to diagnose in patients undergoing hematopoietic stem cell transplantation (HSCT). In 2003, a serum enzyme-linked immunosorbent assay (ELISA) test for the detection of galactomannan (a glycoprotein...
6.
Walsh T, Raad I, Patterson T, Chandrasekar P, Donowitz G, Graybill R, et al.
Clin Infect Dis
. 2006 Dec;
44(1):2-12.
PMID: 17143808
Background: Invasive aspergillosis is an important cause of morbidity and mortality in immunocompromised patients. Current treatments provide limited benefit. Posaconazole is an extended-spectrum triazole with in vitro and in vivo...
7.
Brunstein C, Weisdorf D, DeFor T, Barker J, Tolar J, van Burik J, et al.
Blood
. 2006 Jun;
108(8):2874-80.
PMID: 16804113
Umbilical cord blood (UCB) is increasingly used as an alternative source of hematopoietic stem cells for transplantation for patients who lack a suitable sibling donor. Despite concerns about a possible...
8.
Denning D, Marr K, Lau W, Facklam D, Ratanatharathorn V, Becker C, et al.
J Infect
. 2006 May;
53(5):337-49.
PMID: 16678903
Background: Micafungin (FK463) is a new lipopeptide compound (echinocandin) with activity against Aspergillus and Candida species. This study evaluated the safety and efficacy of micafungin in patients with proven or...
9.
10.
van Burik J, Hare R, Solomon H, Corrado M, Kontoyiannis D
Clin Infect Dis
. 2006 Mar;
42(7):e61-5.
PMID: 16511748
To evaluate the activity of posaconazole for treatment of zygomycosis, a disease for which therapeutic options are limited, we conducted a retrospective study including 91 patients with zygomycosis (proven zygomycosis,...